Cargando…

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma

This case represents the challenge and creativity necessary when treating patients with metastatic renal cell carcinoma who have been exposed to multiple lines of therapy. At present, treatment with immune checkpoint inhibition has stabilized and improved the metastatic disease of this patient with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adashek, Jacob J., Salgia, Meghan, Dizman, Nazli, Kessler, Jonathan, Pal, Sumanta K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981597/ https://www.ncbi.nlm.nih.gov/pubmed/29867435 http://dx.doi.org/10.1159/000489995

Ejemplares similares

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
por: Zhang, Yumeng, et al.
Publicado: (2022)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil
por: Bergerot, Paulo G., et al.
Publicado: (2017)

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
por: Dizman, Nazli, et al.
Publicado: (2022)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Organizing Pneumonia Induced by Ablative Radioembolization for the Treatment of Hepatic Metastatic Renal Cell Carcinoma
por: Devcic, Zlatko, et al.
Publicado: (2019)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles
por: Govindarajan, Ameish, et al.
Publicado: (2023)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

The Gut Microbiome and Metastatic Renal Cell Carcinoma
por: Meza, Luis, et al.
Publicado: (2023)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
por: Meza, Luis, et al.
Publicado: (2023)

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2023)

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
por: Yang, Yuanquan, et al.
Publicado: (2022)

1556. Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies
por: Komoda, Kellie, et al.
Publicado: (2018)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study
por: Duarte, Cassandra, et al.
Publicado: (2023)

Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic
por: Salgia, Sabrina, et al.
Publicado: (2021)

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
por: Salgia, Nicholas J., et al.
Publicado: (2021)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
por: Casadei, Chiara, et al.
Publicado: (2019)

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
por: Pal, Sumanta K., et al.
Publicado: (2013)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Radioembolization for the treatment of hepatocellular carcinoma
por: Kim, Hyo-Cheol
Publicado: (2017)

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition
por: Börner, J. H., et al.
Publicado: (2023)

Circulating tumor DNA analysis of metastatic renal cell carcinoma
por: Zhang, Jingbo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dcecg7mtdbm0t22nbcb4rh04ps